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Case Report

Retinal Degeneration due to Enrofloxacin Intoxication in a Cat

Murat ŞAROĞLU, Dilek OLGUN ERDİKMEN*
Department of Surgery, Faculty of Veterinary Medicine, İstanbul University, 34320 Avcılar, İstanbul - TURKEY

Received: 05.07.2007

Abstract: In this case presentation, retinal degeneration due to enrofloxacin intoxication encountered in a domestic short-haired male
cat is discussed. History of the patient revealed that he had received 7.8 mg/kg enrofloxacin twice daily for 10 days. Both pupils were
dilated. Pupillary light reflexes were negative in both eyes. Direct and indirect ophthalmoscopic examinations showed tapetal
hyperreflectivity, and slight attenuation of the retinal blood vessels compared to those of a healthy cat was observed in both retinas.
Follow-up information obtained from the owner by telephone 6, 12, and 18 months later revealed that there had been no
improvement in the cat’s vision, the cat had adapted to blindness, and the pupils remained dilated.
Key Words: Retinal degeneration, enrofloxacin, cat

Bir Kedide Enrofloksasin Toksikasyonuna Bağlı Olarak Gelişen Retina Dejenerasyonu
Özet: Bu olgu sunumunda, kısa tüylü bir evcil kedide enrofloxacin toksikasyonuna bağlı olarak gelişen retina dejenerasyonu
değerlendirildi. Hastanın anemnezinde 10 gün boyunca, günde iki kez 7,8 mg/kg enrofloxacini peros aldığı öğrenildi. Hastanın klinik
muayenesinde her iki pupillanın dilate olduğu izlendi. Her iki gözde pupillar ışık refleksi negatifti. Direkt ve endirekt oftalmoskobik
muayenede, her iki gözde de normal bir kediye göre tapetal hiperrefleksi geliştiği ve retina damarlarının hafif inceldiği belirlendi.
Hastanın uzun dönem bilgileri 6, 12 ve 18. ayda telefonla sahibinden alındı. Buna göre hastanın görüşünde bir iyileşme olmadığı,
körlüğe adapte olduğu ve her iki puppillanın geniş kaldığı öğrenildi.
Anahtar Sözcükler: Retina dejenerasyonu, enrofloxacin, kedi

Introduction
In small animal practice, intoxications caused by
various drugs are encountered occasionally. Among the
systemic drugs used in cats, it is known that griseofulvin
(1-3), methylnitrosourea-ketamine combination (1,2,4),
and fluoroquinolones (1,3,5-8) may cause damage to the
retina. Enrofloxacin is a fluoroquinolone derivative
antibacterial drug that has been used extensively in small
animal practice in recent years (since 1990). However, it
has been shown to cause retinal degeneration in cats
(1,5,6,8-12). When the drug was first introduced, a
general and wide dose interval of 10-20 mg/kg was
recommended for cats and dogs. However, after the
discovery of the possibility of the active ingredient causing
retinal degeneration, the manufacturer reduced the

recommended dose for cats to 2.5 mg/kg twice a day
(1,5,6).
Initial findings in cats developing retinal degeneration
due to enrofloxacin toxicity are loss of vision, blindness,
and mydriasis. Fundoscopic findings are tapetal
hyperreflectivity and attenuation of the retinal blood
vessels (1,3,5,6,8-10,12). Electroretinographic findings
obtained from cats with retinal degeneration due to
enrofloxacin showed nonrecordable traces (1,3,5,12). In
their 2001 study, Gelatt et al. (5) summarised the
histopathological retinal appearances of such patients as
follows: diffuse degeneration, particularly in the outer
nuclear and photoreceptor layers, and hypertrophy of the
retinal pigment epithelium.
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Factors thought to influence the possibility of retinal
degeneration developing in cats given enrofloxacin are
age, hepatic or renal failure, dosage and duration of the
drug, and route of administration. On the basis of these
factors, in old patients with hepatic or renal failure given
enrofloxacin at a high dose for a long period, the risk of
retinal degeneration developing rises. Conversely,
degeneration may also develop in patients administered
low doses for a short period of time. This could indicate
that this rarely observed retinal degeneration may
develop due to individual predisposition or sensitivity
(1,3).
Loss of vision and total blindness are permanent in the
vast majority of patients (1,3,5-8). However,
improvement of impaired vision was seen when the drug
was discontinued in patients diagnosed early and receiving
low doses of enrofloxacin (1,3,5,8).
Historical findings are very important in the diagnosis
of retinal degeneration. In cats receiving enrofloxacin,
sudden development of mydriasis, delayed and diminished
pupillary light reflexes, reduction or loss of the menace
reflex, and marked loss of vision suggest retinal
degeneration due to enrofloxacin intoxication (1,3,5).
Other causes of retinal degeneration in cats such as
nutritional deficiencies, intraocular inflammatory
conditions, systemic hypertension, genetic abnormalities,
glaucoma, chorioretinitis, and retinal detachment are
conditions that should be considered in the differential
diagnosis (1,3,6).

become dilated during this period. The owner stated that
the cat’s behaviour inside the house was normal initially
and that they had noticed a previously nonexistent green
shine in the depth of the eye. Blindness developed in the
patient despite enrofloxacin administration being stopped
on day 10.
The general condition of the patient was good on
clinical examination. The menace test and cotton ball test
were used to assess vision. Results of these tests were
negative. Both pupils were dilated (Figure). Pupillary light
reflexes were negative in both eyes. Therefore, a fundus
examination was carried out without the use of
mydriatics. Direct and indirect ophthalmoscopic
examinations showed tapetal hyperreflectivity (Figure)
and slight attenuation in the retinal blood vessels
compared to what is found in healthy cats was observed
in both retinas. No dysplastic area or pigment abnormality
was seen either in the tapetal or in the non-tapetal region.
There were no systemic findings in the patient to suggest
kidney or liver failure or any other ocular disease such as
intraocular inflammation, glaucoma, chorioretinitis, or
retinal detachment.
In the light of the historical, clinical, and
ophthalmoscopic findings, the patient was diagnosed with
retinal degeneration due to enrofloxacin intoxication. The
patient’s condition was explained to the owner. This
person was informed that in some mild cases and when

This case is presented in order to bring this topic to
the attention of practising small animal veterinarians and
to share our findings of the condition, which is also
encountered in Turkey.

Case History
A 15-year-old domestic short-haired male cat
weighing 3.2 kg was brought to our clinic with dilated
pupils and blindness in both eyes. History of the patient
revealed that he had suffered an upper respiratory tract
infection 20 days previously and had received 50 mg
enrofloxacin per day orally (25 mg in the morning and 25
mg in the evening) upon the recommendation of the local
veterinary surgeon. It was reported that the initial
complaint regressed 1 week after the treatment was
started, but that the drug had been administered for a
further 3 days and both pupils were noticed to have
404

Figure. Pupillary dilatation and tapetal hyperreflectivity in the case
described.
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low dose administration is stopped after a short period
spontaneous recovery may occur. However, the extremely
high dose of the drug and the 10-day administration
period caused the prognosis to be poor. It is probably due
to the death of the photoreceptors; they cannot
regenerate and therefore the patient will remain blind.
Follow-up information obtained from the owner by
telephone 6, 12, and 18 months later revealed that there
had been no improvement in the cat’s vision. The cat had
adapted to blindness and the pupils remained dilated.

Results and Discussion
As wide-spectrum antibiotics, fluoroquinolones have
been used extensively in recent years in small animal
practice. Enrofloxacin is a member of this group of drugs.
However, clinical results have revealed that it can have a
toxic effect on the retina of cats. The mechanism by which
the drug causes retinal degeneration is still unknown
(1,3,5-8,11,12). However, pharmacological studies
suggest that the blood-brain barrier in cats may be
relatively open to the lipophylic portion of enrofloxacin.
Therefore, high concentrations of enrofloxacin may
accumulate in the central nervous system of cats (11).
Ford et al. (12) observed some behavioural (marked
caution, lethargy, and unkempt coat) and neurological
abnormalities that included incoordination, tremors,
convulsions, blindness, circling, nystagmus, and ptyalism.
In their study comprising 17 cats, Gelatt et al. (5)
reported affected cats to be aged between 3 and 16
years. Doses of enrofloxacin administered orally to these
patients ranged from 4.6 mg/kg once daily to 27 mg/kg
twice daily. The daily dose administered orally to the cat
in the present study was 7.8 mg/kg twice daily. When it
is considered that the manufacturer reduced its initial
recommended daily dose of 11 to 2.5 mg/kg following
the discovery of the drug’s retinotoxic effects, it is clear
that the dose administered to this cat was sufficient to
cause a retinatoxic effect. Gelatt et al. (5) observed that,
while the blindness and mydriasis noticed by the patient’s
owner were variable, this condition was more evident
between 2-3 days and 12 weeks after drug
administration. In our study, the owner had used the drug
for 10 days and noticed dilation of the cat’s pupils 2-3
days before cessation of administration. Blindness became
evident 2 days after the drug was discontinued.

It has been reported that individual predisposition is
important in retinal degeneration caused by enrofloxacin
(1,8). However, factors such as high dose, long duration,
advanced age of the patient, and kidney or liver failure are
thought to be causative factors in the development of
degenerative changes and their severity (3,4,8). Despite
there being no evidence of liver or kidney failure in our
patient, it is interesting that the cat was 15 years old.
No findings related to other causes of retinal
degeneration such as nutritional deficiencies, systemic
hypertension, genetic abnormalities, intraocular
inflammatory diseases, glaucoma, chorioretinitis, or
retinal detachment were encountered in this case (1,6).
Findings such as bilateral pupillary dilatation,
diminished and incomplete pupillary light reflexes, tapetal
hyperreflectivity, and attenuation of retinal blood vessels
observed in our patient are consistent with data from the
literature (1,3,5-8,12). However, findings such as
pigment abnormalities (increase in pigmentation or
hyperpigmentation) and progressive reduction in the
diameter of the optic nerve head observed in some cases
by Gelatt et al. (5) were not encountered in this case. In
young, healthy cats administered enrofloxacin at a daily
oral dose of 50 mg/kg, Ford et al. (10) reported that
fundoscopic changes began within 3 days, attenuation of
retinal blood vessels was observed between 2 and 4 days,
and tapetal hyperreflecivity developed between 5 and 7
days. Our patient had received the drug for 10 days and
was examined 10 days after the drug was stopped.
Therefore, the onset period of the mentioned changes
was not observed.
In some patients with retinal degeneration due to
enrofloxacin intoxication, after cessation of the drug an
improvement in the loss of vision was observed (5,8,11).
In our case, there was total and permanent loss of vision
and no improvement was observed according to the cat’s
owner.
In conclusion, the use of systemic enrofloxacin in cats
should not exceed a total daily dose of 2.5 mg/kg,
duration of administration should be minimal, the drug
should not be used intravenously, and the patient should
be monitored with respect to mydriasis and fundoscopic
changes throughout the treatment period.
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